ClinicalTrials.gg
RecruitingNCT07414277TRANSIT-CGMUpdated Jun 24, 2026

CGM for Insulin-Treated T2DM During Post-Discharge Transition

An interventional study of RT-CGM and SMBG in Type 2 Diabetes Mellitus (T2DM), sponsored by Shanghai 6th People's Hospital. Recruiting at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Shanghai 6th People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital — 6 open to participants now, 7 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Shanghai 6th People's Hospital.

Started
2026
with 2 others
No phase
7 of 11
3 open now
Registered
10th of 11
by date

Among the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, this one is one of 3 that started in 2026, is one of 7 with no phase, and was the 10th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes Mellitus, Type 2 by Shanghai 6th People's Hospital, or all of them as a file.
02

Study summary

The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period.

A total of 160 eligible participants will be randomized in a 1:1 ratio to either the RT-CGM group or the SMBG group. Participants will wear RT-CGM intermittently (every 4 weeks) or perform SMBG for the 12-week intervention period. They will also visit the clinic at Week 12 and Week 24 for follow-up assessments.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • continuous glucose monitoring
  • insulin-treated
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 80 years (inclusive).
  2. Confirmed diagnosis of type 2 diabetes mellitus (T2DM).
  3. between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening/enrollment.
  4. Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed/confirmed by the treating physician (principal physician).

Exclusion criteria

Exclusion Criteria:

  1. Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment.
  2. Severe skin disease at the sensor insertion site, or allergy to adhesive tape/adhesives.
  3. Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period.
  4. Currently participating in, or planning to participate in, another clinical trial.
  5. Current use of oral therapy, or anticipated use during the trial period.
  6. Severe liver disease, defined as (ALT) or aspartate aminotransferase (AST) >3 times the (ULN).
  7. Severe renal impairment or end-stage renal disease, defined as estimated (eGFR) \<30 mL/min/1.73 m².
  8. Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand/comply due to speech/language impairment; or presence of psychiatric disorders.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Intervention group (RT-CGM Group)

    Participants in this group will use a Real-Time Continuous Glucose Monitoring (RT-CGM) system intermittently during the 12-week intervention period, followed by a 14-week follow-up period.

    Device: RT-CGM

  • Active comparator
    Control Group (SMBG Group)

    Participants in this group will perform standard Self-Monitoring of Blood Glucose (SMBG) using a blood glucose meter throughout the 12-week intervention period, followed by a 14-week follow-up period.

    Device: SMBG

Interventions

  • DeviceRT-CGM

    RT-CGM can provide real-time tracking of glucose levels, and offer glucose trend graphs and user-configurable low and high glucose alerts.

  • DeviceSMBG

    SMBG provides discrete, point-in-time capillary blood glucose measurements via fingerstick testing.

06

What researchers measure

Primary outcomes

  1. Difference between change in HbA1c between the intervention group and the control group at Week 12

    HbA1c, expressed as %

    Time frame: from baseline to Week 12

Secondary outcomes

  1. Difference between change in HbA1c between the intervention group and the control group at Week 24

    HbA1c, expressed as %

    Time frame: from baseline to Week 24

  2. Difference in CGM Time in Range (TIR) (3.9-10.0 mmol/L) between the intervention group and the control group at Week 14 and Week 26

    Percent

    Time frame: at Week 14 and Week 26

  3. Difference in CGM Time Above Range (TAR) (>10.0 mmol/L; >13.9 mmol/L) between the intervention group and the control group at Week 14 and Week 26

    Percent

    Time frame: at Week 14 and Week 26

  4. Difference in CGM Time Below Range (TBR) (<3.9 mmol/L; <3.0 mmol/L) between the intervention group and the control group at Week 14 and Week 26

    percent

    Time frame: at Week 14 and Week 26

  5. Difference in CGM coefficient of variation (CV) between the intervention group and the control group at Week 14 and Week 26

    percent

    Time frame: at Week 14 and Week 26

  6. Difference between change in self-efficacy score between the intervention group and the control group at Week 12 and Week 24

    Measured by Diabetes Management Self-efficacy Scale (DMSES) ;Total score ranges from 0 to 200 (0 to 10 per item across 20 items);Higher scores mean: A better outcome (indicating higher self-efficacy in managing diabetes).

    Time frame: from baseline to Week 12 and Week 24

  7. Difference between change in diabetes-related distress between the intervention group and the control group at Week 12 and Week 24

    Measured by the Diabetes Distress Scale (DDS);Total score ranges from 17 to 102 (1 to 6 per item across 17 items);Higher scores mean: A worse outcome (indicating higher levels of diabetes-related distress).

    Time frame: from baseline to Week 12 and Week 24

  8. Difference between change in glucose monitoring satisfaction between the intervention group and the control group at Week 12

    Measured by the Glucose Monitoring Satisfaction Scale (GMSS), Version: Type 2 Diabetes;Total score ranges from 15 to 75 (1 to 5 per item across 15 items);Higher scores mean: A better outcome (indicating higher satisfaction with glucose monitoring).

    Time frame: from baseline to Week 12 and Week 24

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 16 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartActual
May 11, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07414277
Lead sponsor
Shanghai 6th People's Hospital
Collaborators
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Fengxian District Central Hospital, Shanghai 7th People's Hospital
Responsible party
Jian Zhou (Principal Investigator, Professor, Chief Physician, Director, Shanghai 6th People's Hospital) — Principal investigator
First posted
Feb 17, 2026
Start date
May 11, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Jian Zhou
Contact
zhoujian@sjtu.edu.cn
86-21-64369181
Jian Zhou
principal investigator · Shanghai 6th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion